ArticleScientific reports2025
Genome-wide screening and validation of exosome-derived TLN1 as a regulator of epithelial-mesenchymal transition in lung cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Small Extracellular Vesicle-TLN1 Modulates Gastric Cancer Cells and Remodels Lymphatic Endothelial Cells Through AKT Activation to Potentiate Lymphatic Metastasis.Cell biology international · 2026Article
- Oncogenic role of talin-1 in glioma: Association with poor prognosis and regulation of the TGF-beta signaling pathway.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In addition to embryonic development, wound healing, and tissue fibrosis, epithelial-mesenchymal transition (EMT) is another process that enhances tumor invasiveness and metastatic activity. Exosomes transport a variety of bioactive components between cells and are crucial for cell‒cell communication in multiple complex biological processes, including cancer. Although a few studies have shown that exosomes encapsulate microRNAs that induce a pro-EMT tumor microenvironment, a systematic survey of potential EMT-related regulators in lung cancer exosomes is still lacking. To identify exosome-related EMT signals that could be employed for precise cancer diagnosis, we used a computational approach to generate a list of candidates EMT regulators and performed experimental validation in lung cancer cell lines. Particularly, we focused on exosome-derived differentially expressed genes that were not previously reported to be associated with lung cancer. We identified 25 exosome-derived protein coding regulators associated with EMT with aberrant transcript expression in both lung squamous cell carcinoma and lung adenocarcinoma. By focusing on clinical features such as survival time, smoking status, tumor purity, and primary tumor subtypes, we found that these 25 genes are important for lung cancer development based on a combined cohort of 9781 lung cancer samples from 24 independent genomics studies. By validating two examples of upregulated and downregulated exosome-derived regulators, we confirmed that TLN1 is a potential oncogene in lung cancer progression, which suggests that it may serve as a diagnostic marker. In summary, our results provide a potential exosome-based biomarker for cancer diagnosis that could be used as a therapeutic tool to control the occurrence of EMT and affect cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.